tiprankstipranks
Trending News
More News >

Solvonis Therapeutics Gains Research Coverage from Singer Capital Markets

Story Highlights
  • Solvonis Therapeutics is a biopharmaceutical company developing treatments for addiction and mental health.
  • Singer Capital Markets has initiated research coverage on Solvonis, boosting its market visibility.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Solvonis Therapeutics Gains Research Coverage from Singer Capital Markets

Don’t Miss TipRanks’ Half-Year Sale

Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an update.

Solvonis Therapeutics plc announced that Singer Capital Markets has initiated equity research coverage on the company, highlighting its innovative approach in the biopharmaceutical industry. This development could enhance Solvonis’s visibility and credibility among institutional investors, potentially impacting its market positioning and stakeholder interest positively.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Based in London and listed on the London Stock Exchange, the company is advancing a pipeline of repurposed and novel compounds targeting neuropsychiatric conditions such as Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). Solvonis is also leveraging an AI-supported discovery platform to address depression and stimulant use disorders.

Average Trading Volume: 46,750,651

Technical Sentiment Signal: Hold

Current Market Cap: £10.64M

See more data about SVNS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1